课题基金 / 基金详情

ESTIMATION OF ORAL CYSTEAMINE BITARTRATE AT STEADY STATE IN CYSTINOSIS

ESTIMATION OF ORAL CYSTEAMINE BITARTRATE AT STEADY STATE IN CYSTINOSIS
胱氨酸中毒稳态时口服半胱胺酒石酸氢盐的估计
批准号：
6265204
负责人：
JERRY A SCHNEIDER
金额：
$1.15万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265204
关键词：
blood chemistry clearance rate clinical research cysteamine cystinosis dosage drug screening /evaluation human subject human therapy evaluation leukocytes longitudinal human study metabolism disorder chemotherapy oral administration

项目摘要

项目成果

JERRY A SCHNEIDER的其他基金

相似基金

相关文献

中文摘要
翻译
在给药后5、1、1.5、2、3和6小时抽血以确定已达到其最大剂量胱抑素并已维持该剂量至少6个月的患者中的白色血细胞胱氨酸和血浆半胱胺水平。 评价患者6小时给药间隔内的胱抑素清除率。
英文摘要
Blood draws to determine white blood cell cystine and plasma cysteamine levels at hours .5, 1, 1.5, 2,3 and 6 post dosing in patients who have reached their maximum dose of cystagon and who have maintained this dose for at least 6 months. Evaluate the clearance of cystagon over the patient's 6 hour dose interval.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DO LEUKOCYTES NEED TO BE SEPARATED FROM WHOLE BLOOD FOR CYSTINE LEVELS
DO LEUKOCYTES NEED TO BE SEPARATED FROM WHOLE BLOOD FOR CYSTINE LEVELS
DIAGNOSIS AND MONITORING OF PATIENTS WITH CYSTINOSIS
DIAGNOSIS AND MONITORING OF PATIENTS WITH CYSTINOSIS
海外基金